SavedAdd your journal

Journals / Ulusal Romatoloji Dergisi / 2020 / Cilt: 12 - Sayı: 2

Low dose colchicine use in familial Mediterranean fever patients whose disease is under control

Hastalığı kontrol altında olan ailevi Akdeniz ateşi hastalarında düşük doz kolşisin kullanımı

Nilüfer Alpay KANITEZ
Cemal BES
Selda ÇELİK
Sogol SADRİ
Emine AŞCI
Gamze ERGÜN
Ozan Cemal İÇAÇAN
Pages
30–34
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

FMF patients, those have an ISSF score ≤2, were divided into two groups regarding to their average daily colchicine dose as low dose group (

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The initial dose of colchicine recommended for the treatment of familial Mediterranean fever (FMF) is 1-1.5 mg/day in adults.
📊
Key Findings & Data:The aim of this study is to identify FMF patients with mild or controlled disease, who can reduce colchicine doses.
💡
Conclusion & Impact:FMF patients, those have an ISSF score ≤2, were divided into two groups regarding to their average daily colchicine dose as low dose group (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The initial dose of colchicine recommended for the treatment of familial Mediterranean fever (FMF) is 1-1.5 mg/day in adults. The aim of this study is to identify FMF patients with mild or controlled disease, who can reduce colchicine doses. Methods: International severity scoring system score (ISSF) for FMF was calculated to determine the severity of disease in FMF patients admitted to our clinic. FMF patients, those have an ISSF score ≤2, were divided into two groups regarding to their average daily colchicine dose as low dose group (

Özet

Ailevi Akdeniz ateşi (AAA) hastalığında tedavisinde önerilen kolşisin başlangıç dozu yetişkinlerde 1-1,5 mg/gündür. Bu çalışmanın amacı kolşisin dozlarını azaltan hafif ya da hastalığı kontrol altında olan AAA hastalarının belirlenmesidir. Yöntem: Kliniğimize başvuran AAA hastalarında hastalık şiddetini belirlemek için ‘international severity scoring system for familial Mediterranean fever’ (ISSF) puanı hesaplandı. ISSF skoru ≤2 olan hastalar, düşük doz (ortalama günlük kolşisin dozu

🔖

Cite This Article

KANITEZ, N. A., BES, C., ÇELİK, S., SADRİ, S., AŞCI, E., ERGÜN, G., İÇAÇAN, O. C. (2022). Low dose colchicine use in familial Mediterranean fever patients whose disease is under control. Ulusal Romatoloji Dergisi, Cilt: 12 - Sayı: 2, 30–34. https://ajindex.com/articles/643911

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Toplak N, Frenkel J, Ozen S, et al. Paediatric Rheumatology International Trials Organisation (PRINTO), Eurotraps and Eurofever Projects. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis 2012;71:1177-82
  2. Ozen S, Demirkaya E, Erer B, et al. Eular recommendations for the management of familia Mediterranean fever. Ann Rheum Dis 2016;75:644-51
  3. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879-85
  4. Stankovic Stojanovic K, Hentgen V, et al. Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: A study of 218 patients. Clin Biochem 2017;50:206-9
  5. Demirkaya E, Acikel C, Hashkes, et al. FMF Arthritis Vasculitis and Orphan disease Resarch in pediatric rheumatology (FAVOR). Development and initial validation of international severity sc oring system for familial Mediterranean fever (ISSF). Ann Rheum Dis 2016;75:1051-6
  6. Tunca M, Akar S, Onen F, et al. Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005;84:1-11
  7. Üreten K, Gönülalan G, Akbal E, et al. Demographic, clinical and mutational characteristics of Turkish familial Mediterranean fever patients: results of a single center in Central Anatolia. Rheumatol Int 2010;30:911-5
  8. Mor A, Shinar Y, Zaks N, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 2005;35:57-64
  9. Ben-Zvi I, Krichely-Vachdi T, Feld O, Lidar M, Kivity S, Livneh A. Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study. Orphanet J Rare Dis 2014;9:9-3
  10. Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livaneh A. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003;48:1149-55
  11. Knieper AM, Klotsche J, Lainka E, et al. Familial Mediterraneanfever in children and adolescents: factors for colchicine dosage and predicting parameters for dose increase. Rheumatology (Oxford) 2017;56:1597-1606
  12. La Regina M, Ben-Chetrit E, Gasparyan AY, Livaneh A, Ozdogan H, Manna R. Current trends in colchicine treatment in familial Mediterranean fever. Clin Exp Rheumatol 2013;31:41-6.